# A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

> **NCT03837353** · PHASE1,PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 18 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** DKN-01
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03837353
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-01
- **Primary completion:** 2022-07-19
- **Final completion:** 2022-09-20
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Terminated early due to slow accrual in the context of changing practice patterns.
- **Last updated:** 2023-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03837353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03837353, "A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03837353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*